Session Time: 11:15am-12:45pm
Location: Research Hub - Kiosk 3
Disclosures: Ellen Dzierzak, MPH : Nothing to disclose
Case Description: The patient presented to the emergency room with a 2-hour history of esotropia in right eye with blurry vision. The vision was clear when the patient had one eye closed. She also reported a frontal headache lasting for last 3 hours. The patient denied dizziness, weakness, tingling, nausea, vomiting. She had never had anything similar in the past. The patient denied daily prescription medications, tobacco, alcohol, and illicit drug use. With further questioning, the patient’s mother admitted to giving her daughter weight loss supplements. On further investigation, the weight loss supplements contain, the central nervous system stimulant, Octodrine.
Setting: Pediatric Emergency room
Patient: 14-year-old female with no past medical history.
Assessment/Results: The patient’s toxic screen was positive for amphetamines. All other testing was negative.
Discussion: This is not the first reported case of false positive amphetamine with these weight loss weight supplements containing the octodrine product. This is may be the first reported case of transient esotropia with this supplementation.
Conclusion: There are serious adverse effects that can occur from weight loss supplementation in young athletes that are not properly studied in this population.
Level of Evidence: Level V
To cite this abstract in AMA style:Dzierzak E, Tamboli SH. Adverse Effects of Weight Loss Supplements in Young Athletes [abstract]. PM R. 2019; 11(S2)(suppl 2). https://pmrjabstracts.org/abstract/adverse-effects-of-weight-loss-supplements-in-young-athletes/. Accessed September 28, 2023.
« Back to AAPM&R Annual Assembly 2019
PM&R Meeting Abstracts - https://pmrjabstracts.org/abstract/adverse-effects-of-weight-loss-supplements-in-young-athletes/